Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.45 |
| ▸ | HTR6 | P50406 | 8/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.40 |
| ▸ | QDPR | P09417 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8214687 | 0.79 | HTR2C (0.50) | HTR2CHTR6CCNT1CDK9SIGMAR1 | |
| SCHEMBL6870916 | 0.76 | CCR1 (0.41) | MAPTQDPRMEN1KMT2AKDM4E | |
| SCHEMBL27598375 | 0.75 | HTR2C (0.46) | HTR2CHTR6CCNT1CDK9SIGMAR1 | |
| SCHEMBL27598376 | 0.73 | HTR2C (0.46) | HTR2CHTR6CCNT1CDK9SIGMAR1 | |
| SCHEMBL14540630 | 0.73 | HTR2C (0.46) | HTR2CHTR6CCNT1CDK9SIGMAR1 | |
| SCHEMBL5232835 | 0.73 | CNR1 (0.51) | HTR6 | |
| SCHEMBL4329636 | 0.71 | HTR2C (0.60) | HTR2CHTR6CCNT1CDK9SIGMAR1 | |
| SCHEMBL20280298 | 0.71 | LMNA (0.48) | HTR2CMAPTHTR2AMEN1KMT2A | |
| SCHEMBL4329522 | 0.71 | HTR2C (0.55) | HTR2CHTR6CCNT1CDK9SIGMAR1 | |
| SCHEMBL31700695 | 0.69 | CCNT1 (0.42) | HTR2CHTR6CCNT1CDK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1383501-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1383501-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-04-04 | — | — | EP | disclosed |
| EP-1383501-A4 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2005-10-12 | — | — | EP | disclosed |
| CN-1633297-A | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2005-06-29 | — | — | CN | disclosed |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | UJJAINWALLA FEROZE | 2004-12-30 | — | — | US | disclosed |
| US-6818658-B2 | TREATING OBESITY, DIABETES, SEXUAL DYSFUNCTION, INCLUDING ERECTILE DYSFUNCTION AND FEMALE SEXUAL DYSFUNCTION. | MERCK & CO., INC. | 2004-11-16 | — | — | US | disclosed |
| EP-1383501-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2003-12-04 | — | — | US | disclosed |
| WO-2002068388-A2 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225060-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | HTR2C 153/4885HTR6 368/4885CCNT1 4618/4885 |
| US-20040266821-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | HTR2C 153/4885HTR6 368/4885CCNT1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.